IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York
IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York
Read moreMon, 19th Oct 2020 08:34
IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York
Read more(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced its intention to cancel its shares from trading on AIM on Monday, with effect on 11 January.
Read moreTRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill
Read more(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma updated the market on patents for its lead development candidate 'Oleogel-S10' on Tuesday, as well as its recently-acquired and third commercial product 'Mycapssa'.
Read moreIN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition
Read moreIN BRIEF: Amryt hikes guidance on record second quarter results
Read more(Sharecast News) - Amryt Pharma reported record second quarter results on Friday, raising its full-year guidance, as revenue in the three months ended 30 June came in at $62.8m, up from $46.2m year-on-year.
Read moreEXECUTIVE CHANGES: HL CFO to depart; Novacyt hires CEO from Amryt
Read more(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.
Read moreBUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall
Read more(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced on Thursday that the United States Food and Drug Administration (FDA) has granted priority review status for the new drug application for 'Oleogel-S10', for the treatment of epidermolysis bullosa (EB).
Read moreTRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows
Read moreTRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million
Read moreEXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start
Read more(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has completed the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for 'Oleogel-S10', it announced on Wednesday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB).
Read more